Small-molecule arginase inhibitors

Pharmaceutical Patent Analyst

Volumn 3, Issue 1, 2014, Pages 65-85

  Ivanenkov, Yan A ^a,b   Chufarova, Nina V ^a  

^a MOSCOW INSTITUTE OF PHYSICS AND TECHNOLOGY   (Russian Federation)

^b CHEMDIV INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

( 2 BORONOETHYL) LEVO CYSTEINE; AMINO 6 (BORONO)HEXANOIC ACID; ARGINASE INHIBITOR; HYDROLASE INHIBITOR; UNCLASSIFIED DRUG; ARGINASE; ENZYME INHIBITOR;

CRYSTAL STRUCTURE; DRUG ANALYSIS; DRUG POTENCY; DRUG STRUCTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CARDIOVASCULAR DISEASE; CHEMISTRY; COMMUNICABLE DISEASE; DRUG ANTAGONISM; ENZYMOLOGY; LEGAL ASPECT; METABOLISM; PATENT; X RAY CRYSTALLOGRAPHY;

ANIMALS; ARGINASE; CARDIOVASCULAR DISEASES; COMMUNICABLE DISEASES; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; PATENTS AS TOPIC;

EID: 84906527164     PISSN: 20468954     EISSN: 20468962     Source Type: Journal    
DOI: 10.4155/PPA.13.75     Document Type: Review

References (39)

1. Kossel A DH. Über die Arginase. Hoppe-Seyler's Z. Physiol. Chem. (41), 321-331 (1904).
2. Ash DE. Structure and function of arginases. J. Nutr. 134(10 Suppl.), 2760S-2767S (2004).
3. Maarsingh H, Zaagsma J, Meurs H. Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives. Br. J. Pharmacol. 158 (3), 652-664 (2009).
4. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem. J. 336(Pt 1), 1-17 (1998).
5. Munder M. Arginase: an emerging key player in the mammalian immune system. Br. J. Pharmacol. 158(3), 638-651 (2009).
6. Mclarren KW, Cole AE, Weisser SB et al. SHIP-deficient mice develop spontaneous intestinal inflammation and arginase-dependent fibrosis. Am. J. Pathol. 179(1), 180-188 (2011).
7. Kavalukas SL, Uzgare AR, Bivalacqua T.J., Barbul A. Arginase inhibition promotes wound healing in mice. Surgery 151 (2), 287-295 (2012).
8. Rotondo R, Barisione G, Mastracci L et al. IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. Int. J. Cancer 125(4), 887-893 (2009).
9. Brittenden J, Heys SD, Ross J, Park K.G., Eremin O. Nutritional pharmacology: effects of L-arginine on host defences, response to trauma and tumour growth. Clin. Sci. (Lond.) 86(2), 123-132 (1994).
10. Heby O, Persson L, Rentala M. Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis. Amino Acids 33(2), 359-366 (2007).
11. Benson RC, Hardy KA, Morris CR Arginase and arginine dysregulation in asthma. J. Allergy (Cairo) 736319 (2011).
12. Morris SM Jr. Recent advances in arginine metabolism: roles and regulation of the arginases. Br. J. Pharmacol. 157(6), 922-930 (2009).
13. Singh R, Pervin S, Karimi A., Cederbaum S, Chaudhuri G. Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res. 60(12), 3305-3312 (2000).
14. D'antonio E.L., Ullman B, Roberts SC et al. Crystal structure of arginase from Leishmania mexicana and implications for the inhibition of polyamine biosynthesis in parasitic infections. Arch. Biochem. Biophys. 535(2), 163-176 (2013).
15. Cao W, Sun B, Feitelson M.A., Wu T., Tur-Kaspa R, Fan Q. Hepatitis C virus targets over-expression of arginase I in hepatocarcinogenesis. Int. J. Cancer 124(12), 2886-2892 (2009).
16. Das P, Lahiri A, Chakravortty D. Modulation of the arginase pathway in the context of microbial pathogenesis: a metabolic enzyme moonlighting as an immune modulator. PLoS Pathog. 6(6), e1000899 (2010).
17. Schulman SP, Becker LC, Kass DA et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 295(1), 58-64 (2006).
18. Morris SM Jr. Arginases and arginine deficiency syndromes. Curr. Opin. Clin. Nutr. Metab. Care 15(1), 64-70 (2012).
19. Dothager RS, Putt KS, Allen B.J., Leslie BJ, Nesterenko V, Hergenrother PJ. Synthesis and identification of small molecules that potently induce apoptosis in melanoma cells through G1 cell cycle arrest. J. Am. Chem. Soc. 127(24), 8686-8696 (2005).
20. Pekol T, Daniels JS, Labutti J et al. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites Drug Metab. Dispos. 33(6), 771-777 (2005).
21. Hubbard SA. Comparative toxicology of borates. Biol. Trace Elem. Res. 66(1-3), 343-357 (1998).
22. Car BD, Flint OP Oberdoerster J, Price J, Foster WR, Gemzik B, Berman D. Tanespimycin reverses bortezomib-induced inhibition of granulopoiesis. Blood 114,
23. Baggio R, Emig FA, Christianson D.W., Ash DE, Chakder S, Rattan S. Biochemical and functional profile of a newly developed potent and isozyme-selective arginase inhibitor. J. Pharmacol. Exp. Ther. 290(3), 1409-1416 (1999).
24. Busnel O, Carreaux F, Carboni B et al. Synthesis and evaluation of new omega-borono-alpha-amino acids as rat liver arginase inhibitors. Bioorg. Med. Chem. 13(7), 2373-2379 (2005).
25. Jeon YH, Heo YS, Kim CM et al. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell. Mol. Life Sci. 62(11), 1198-1220 (2005).
26. Di Costanzo L., Sabio G, Mora A et al. Crystal structure of human arginase I at 1.29-A resolution and exploration of inhibition in the immune response. Proc. Natl Acad. Sci. USA 102(37), 13058-13063 (2005).
27. Cavalli RC, Burke CJ, Kawamoto S, Soprano D.R., Ash DE. Mutagenesis of rat liver arginase expressed in Escherichia coli: role of conserved histidines. Biochemistry 33(35), 10652-10657 (1994).
28. Cox JD, Kim NN, Traish A.M., Christianson DW. Arginase-boronic acid complex highlights a physiological role in erectile function. Nat. Struct. Biol. 6(11), 1043-1047 (1999).
29. Cama E, Pethe S, Boucher JL et al. Inhibitor coordination interactions in the binuclear manganese cluster of arginase. Biochemistry 43(28), 8987-8999 (2004).
30. Kanyo ZF, Scolnick LR, Ash D.E., Christianson DW. Structure of a unique binuclear manganese cluster in arginase. Nature 383 (6600), 554-557 (1996).
31. Di Costanzo L., Ilies M, Thorn K.J., Christianson DW. Inhibition of human arginase I by substrate and product analogues. Arch. Biochem. Biophys. 496(2), 101-108 (2010).
32. Dioguardi FS. To give or not to give? Lessons from the arginine paradox. J. Nutrigenet. Nutrigenomics 4(2), 90-98 (2011).
33. Elms S, Chen F, Wang Y et al. Insights into the arginine paradox: evidence against the importance of subcellular location of arginase and eNOS. Am. J. Physiol. Heart Circ. Physiol. 305(5), H651-H656 (2013).
34. Chow AK, Ng L, Sing Li H et al. Anti-tumor efficacy of a recombinant human arginase in human hepatocellular carcinoma. Curr. Cancer Drug Targets 12(9), 1233-1243 (2012).
35. Arikan-Ayyildiz Z., Karaman M, Tuncel T et al. Beneficial effects of arginase inhibition and inhaled L-arginine administration on airway histology in a murine model of chronic asthma. Allergol. Immunopathol. (Madr.) doi: 10.1016/j.aller.2013.01.001 (2013) (Epub ahead of print).
36. Van Zandt M.C., Whitehouse DL, Golebiowski A et al. Discovery of (R)-2-amino-6-borono-2-(2-(piperidin-1-yl)ethyl) hexanoic acid and congeners as highly potent inhibitors of human arginases I and II for treatment of myocardial reperfusion injury. J. Med. Chem. 56(6), 2568-2580 (2013).
37. Golebiowski A PBR, Van Zandt M, Ji MK et al. 2-Substituted-2-amino-6-boronohexanoic acids as arginase inhibitors. Bioorg. Med. Chem. Lett. 23(7), 2027-2030 (2013).
38. Hernandez V, Crepin T, Palencia A et al. Discovery of a novel class of boron-based antibacterials with activity against gramnegative bacteria. Antimicrob. Agents Chemother. 57(3), 1394-1403 (2013).
39. Thomson Integrity Database. http://integrity.thomson-pharma.com